China’s NMPA Approves Two Separate INDs On The Same Day For Ansun’s Investigational Biologic Compound DAS181 By abadmin|2021-08-26T07:16:45+00:00October 28th, 2019|Uncategorized|0 Comments Read More
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection By abadmin|2021-08-26T07:17:17+00:00May 28th, 2019|Uncategorized|0 Comments Read More
Ansun BioPharma secures $85 million in Series A Financing By abadmin|2021-08-26T07:17:44+00:00May 18th, 2018|Uncategorized|0 Comments Read More
Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181 By abadmin|2021-08-26T07:18:08+00:00October 10th, 2017|Uncategorized|0 Comments Read More
